Companies House 16022972 2025-10-31 2025-10-31 2024-10-16 false iso4217:GBP xbrli:pure 16022972 2025-10-31 16022972 2024-10-16 2025-10-31 16022972 curr:PoundSterling 2024-10-16 2025-10-31 16022972 uk-bus:CompanyLimitedByGuarantee 2024-10-16 2025-10-31 16022972 uk-bus:FRS102 2024-10-16 2025-10-31 16022972 uk-bus:AuditExempt-NoAccountantsReport 2024-10-16 2025-10-31 16022972 uk-bus:FullAccounts 2024-10-16 2025-10-31 16022972 uk-bus:RegisteredOffice 2024-10-16 2025-10-31 16022972 uk-bus:Director1 2024-10-16 2025-10-31 16022972 uk-bus:Director2 2024-10-16 2025-10-31 16022972 uk-bus:Director3 2024-10-16 2025-10-31 16022972 uk-bus:Director4 2024-10-16 2025-10-31 16022972 uk-bus:Director5 2024-10-16 2025-10-31 16022972 uk-bus:Director6 2024-10-16 2025-10-31 16022972 uk-bus:Director7 2024-10-16 2025-10-31 16022972 uk-bus:Director8 2024-10-16 2025-10-31 16022972 uk-bus:Director9 2024-10-16 2025-10-31 16022972 uk-bus:Director10 2024-10-16 2025-10-31 16022972 uk-bus:Director11 2024-10-16 2025-10-31 16022972 uk-bus:Director12 2024-10-16 2025-10-31 16022972 uk-bus:Director13 2024-10-16 2025-10-31 16022972 uk-bus:Director14 2024-10-16 2025-10-31 16022972 uk-bus:Director15 2024-10-16 2025-10-31 16022972 uk-bus:Director16 2024-10-16 2025-10-31 16022972 uk-bus:Director17 2024-10-16 2025-10-31 16022972 uk-bus:Director18 2024-10-16 2025-10-31 16022972 uk-bus:Director19 2024-10-16 2025-10-31 16022972 uk-bus:Director20 2024-10-16 2025-10-31 16022972 uk-bus:Director21 2024-10-16 2025-10-31 16022972 uk-bus:CompanySecretary1 2024-10-16 2025-10-31 16022972 core:AfterOneYear 2025-10-31 16022972 core:WithinOneYear 2025-10-31 16022972 core:WithinOneYear 2024-10-16 2025-10-31 16022972 core:AfterOneYear 2025-10-31 16022972 core:AfterOneYear 2024-10-16 2025-10-31 16022972 core:ShareCapital 2025-10-31 16022972 core:SharePremium 2025-10-31 16022972 core:OtherReservesSubtotal 2025-10-31 16022972 core:RevaluationReserve 2025-10-31 16022972 core:RetainedEarningsAccumulatedLosses 2025-10-31 16022972 1 2024-10-16 2025-10-31 16022972 2 2024-10-16 2025-10-31 16022972 3 2024-10-16 2025-10-31 16022972 core:LandBuildings 2024-10-16 2025-10-31 16022972 core:LandBuildings 2025-10-31 16022972 core:PlantMachinery 2024-10-16 2025-10-31 16022972 core:PlantMachinery 2025-10-31 16022972 core:FurnitureFittingsToolsEquipment 2024-10-16 2025-10-31 16022972 core:FurnitureFittingsToolsEquipment 2025-10-31 16022972 core:OfficeEquipment 2024-10-16 2025-10-31 16022972 core:OfficeEquipment 2025-10-31 16022972 core:Vehicles 2024-10-16 2025-10-31 16022972 core:Vehicles 2025-10-31 16022972 core:NetGoodwill 2024-10-16 2025-10-31 16022972 core:NetGoodwill 2025-10-31 16022972 core:IntangibleAssetsOtherThanGoodwill 2024-10-16 2025-10-31 16022972 core:IntangibleAssetsOtherThanGoodwill 2025-10-31

# CLINICALLY VULNERABLE FAMILIES CIC

## Company limited by guarantee

## Company Registration Number:
16022972 (England and Wales)

## Unaudited statutory accounts for the year ended 31 October 2025

## Period of accounts

## Start date: 16 October 2024

## End date: 31 October 2025

# CLINICALLY VULNERABLE FAMILIES CIC

## Contents of the Financial Statements

for the Period Ended 31 October 2025

Balance sheet |
Additional notes |
Balance sheet notes |
Community Interest Report |

# CLINICALLY VULNERABLE FAMILIES CIC

## Balance sheet

As at 31 October 2025

| Notes | 13 months to 31 October 2025
--- | --- | ---
|  | £
Current assets
Cash at bank and in hand: |  | 712 |
Total current assets: |  | 712
Creditors: amounts falling due within one year: | 3 | ( 607 ) |
Net current assets (liabilities): |  | 105
Total assets less current liabilities: |  | 105
Total net assets (liabilities): |  | 105
Members' funds
Profit and loss account: |  | 105 |
Total members' funds: |  | 105

The notes form part of these financial statements

# CLINICALLY VULNERABLE FAMILIES CIC

## Balance sheet statements

For the year ending 31 October 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen not to file a copy of the company's profit and loss account.

This report was approved by the board of directors on 6 July 2026
and signed on behalf of the board by:

Name: Sarah Louise Steven
Status: Director

The notes form part of these financial statements

# CLINICALLY VULNERABLE FAMILIES CIC

## Notes to the Financial Statements

for the Period Ended 31 October 2025

- ## 1. Accounting policies

  Basis of measurement and preparation

  These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

  Turnover policy

  Turnover comprises the invoiced value of goods and services supplied by the company plus grants received, net of Value Added Tax (where VAT registered) and trade discounts.

# CLINICALLY VULNERABLE FAMILIES CIC

## Notes to the Financial Statements

for the Period Ended 31 October 2025

- ## 2. Employees

  | 13 months to 31 October 2025
  --- | ---
  Average number of employees during the period | 1 |

# CLINICALLY VULNERABLE FAMILIES CIC

## Notes to the Financial Statements

for the Period Ended 31 October 2025

## 3. Creditors: amounts falling due within one year note

| 13 months to 31 October 2025
--- | ---
| £
Taxation and social security | 25 |
Accruals and deferred income | 270 |
Other creditors | 312 |
Total | 607

# COMMUNITY INTEREST ANNUAL REPORT

### CLINICALLY VULNERABLE FAMILIES CIC

### Company Number: 16022972 (England and Wales)

### Year Ending: 31 October 2025

Company activities and impact

Part 1 - General description of the company's activities and impact Clinically Vulnerable Families CIC was incorporated on 16 October 2024 to benefit Clinically Vulnerable people and the households they live with, across all four nations of the United Kingdom. “Clinically Vulnerable” refers to individuals identified in the COVID-19 Green Book as being at increased risk from infectious disease because of a health condition or age, together with the families and households who live with and support them. During the period 16 October 2024 to 31 October 2025, the company's activities benefited this community as follows: Representing the community's experience through the UK Covid-19 Inquiry. The company acted as a Core Participant in four modules of the UK Covid-19 Inquiry (Modules 3, 4, 8 and 10) and contributed evidence to four further modules. It gathered data and first-hand accounts from Clinically Vulnerable people and prepared organisational and oral witness evidence on their behalf alongside the questioning of key witnesses, ensuring the experiences of this community were placed before the Inquiry. Module 3 oral evidence concluded on 28 November 2024; Module 4 oral evidence hearings opened on 16 January 2025; and CVF also gave oral evidence for the company to Module 8 on 1 October 2025. This gave a voice to a community whose experiences might otherwise have gone unheard within an official process of national importance. Raising public awareness and understanding. The company founded and ran Clinically Vulnerable Awareness Day on 19 July, raising public understanding of the needs of Clinically Vulnerable people. It is also a founder member of World Ventil8 Day, the international awareness day for ventilation and indoor air quality, helping raise public awareness of the importance of clean indoor air for those at higher clinical risk. Improving accessibility of democratic participation. During the period the company carried out its first accessibility audit of polling stations, ahead of the May 2025 local elections, gathering evidence on the barriers Clinically Vulnerable people face in voting safely and sharing its findings with the Electoral Commission, which handles its engagement with the company through its partnership team. Through its own MyMaskMyVote initiative, run each year since 2023, the company raised public awareness of these accessibility barriers and of the measures - such as staff mask-wearing and ventilation - that help Clinically Vulnerable people vote safely. Peer support, information and safer access. Throughout the year the company provided peer support, information-sharing and practical guidance to help Clinically Vulnerable people and their families access healthcare, education and workplaces more safely, and to reduce the isolation experienced by many Clinically Vulnerable households. These activities were carried on for the benefit of the Clinically Vulnerable community across the United Kingdom and the wider public, and not for private gain.

Consultation with stakeholders

The company's stakeholders are the Clinically Vulnerable people and households it exists to serve (who form its membership community), the wider public, and the organisations and institutions whose decisions affect this community, including the UK Covid-19 Inquiry. The company consulted its community through regular online meetings and by maintaining open lines of communication with members throughout the year, supplemented by surveys used to gather members' experiences. Feedback directly shaped the company's activities: the accounts and data gathered from the community informed the written and oral evidence submitted to the UK Covid-19 Inquiry, and members' priorities guided the company's awareness and information work.

Directors' remuneration

During the period, one director received remuneration. The total remuneration paid to directors was £10,287.61. The director served without remuneration during the opening months of the period, and the amount paid represents a modest honorarium. All of the company's assets and surpluses continue to be applied for the benefit of the community in accordance with the asset lock. There were no other transactions or arrangements in connection with the remuneration of directors, or compensation for directors' loss of office, which require to be disclosed.

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
6 July 2026

And signed on behalf of the board by:
Name: Sarah Louise Steven
Status: Director